Heads up, savvy investors: Bristol Myers is getting some love from Wall Street after BofA upgraded the stock, saying the market is sleeping on its future drug pipeline. While the company’s losing exclusivity on some old meds (which usually means a price dip), analysts think this is a rare chance to buy low before new treatments hit. If you like a bargain with comeback potential, keep an eye on BMY. #Business #Market #investing